Specialty Pharma Journal Specialty, Precision & Technology
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced results from GioTag, a real-world retrospective study which examined the impact of first-line Giotrif®/Gilotrif® (afatinib) followed by osimertinib, in epidermal growth factor receptor mutation-positive (EGFR M+) non-small cell lung cancer (NSCLC) patients with acquired T790M mutations, the most common mechanism of resistance to first- and …
Tag Archives: BIPI
October, 2018
September, 2018
-
13 September
Boehringer Ingelheim Acquires All Shares of ViraTherapeutics to Develop Next Generation Viral-Based Immuno-Oncology Therapies
INGELHEIM, Germany–(BUSINESS WIRE)–Boehringer Ingelheim today announced that it has acquired all shares of ViraTherapeutics, a biopharmaceutical company specializing in the development of oncolytic viral therapies. ViraTherapeutics developed the lead candidate VSV-GP (Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP)), which is being investigated alone and in combination with other therapies. …
April, 2018
-
5 April
Boehringer Ingelheim and OSE Immunotherapeutics Enter Immuno-Oncology Partnership
INGELHEIM, Germany & NANTES, France–(BUSINESS WIRE)–Boehringer Ingelheim and OSE Immunotherapeutics, a biotechnology company focused on the development of innovative immunotherapies, today announced a collaboration and exclusive worldwide collaboration and license agreement to jointly develop OSE-172, a SIRP-alpha antagonist targeting myeloid lineage cells. SIRP-alpha is a receptor expressed by myeloid lineage …
November, 2017
-
3 November
Boehringer Ingelheim and Dicerna Partner to Develop Novel Treatments for Chronic Liver Diseases
INGELHEIM, Germany & CAMBRIDGE, Mass.–(BUSINESS WIRE)–Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced a research collaboration and license agreement to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases. The partnership will initially focus on …
June, 2017
-
14 June
Results from Late-Stage Study Demonstrate Clinical Equivalence of Boehringer Ingelheim’s Adalimumab Biosimilar Candidate to Humira
Ingelheim/Germany and Madrid/Spain, June 14, 2017 – Boehringer Ingelheim announced today results from the pivotal Phase III VOLTAIRE®-RA1 study, confirming that its adalimumab biosimilar candidate BI 695501 and HUMIRA®* have similar efficacy, safety and immunogenicity in patients with moderately-to-severely active rheumatoid arthritis. The 24 week results will be presented at …
December, 2016
-
14 December
FDA Approves Synjardy XR Tablets for Adults with Type 2 Diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ — The U.S. Food and Drug Administration (FDA) has approved Synjardy® XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with diet and exercise, SYNJARDY XR is indicated to improve blood sugar in adults with …
October, 2016
-
26 October
Boehringer Ingelheim’s Biosimilar Candidate Shows Similar Efficacy and Safety Profile to Humira in Phase 3 Study
Ingelheim, Germany, 26 October, 2016 – Boehringer Ingelheim today announced top-line results from the pivotal Phase III clinical study of BI 695501, a biosimilar candidate to U.S.-licensed Humira® and EU approved Humira® (adalimumab)*. BI 695501 met the clinical study primary efficacy endpoint to establish equivalence with Humira® in patients with …
April, 2016
-
18 April
FDA Approves Boehringer Ingelheim’s Gilotrif as new Oral Treatment for Squamous Cell Carcinoma of the Lung
RIDGEFIELD, Conn., April 15, 2016 /PRNewswire/ — Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Gilotrif® (afatinib) tablets for the treatment of patients with advanced squamous cell carcinoma of the lung whose disease has progressed after treatment …